Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Publication

Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Journal Paper/Review - Oct 10, 2023

Begré Lorin, Boyd Anders, Salazar-Vizcaya Luisa, Suter-Riniker Franziska, Béguelin Charles, Rockstroh J K, Günthard Huldyrich F, Calmy Alexandra, Cavassini Matthias, Stoeckle Marcel, Schmid Patrick, Bernasconi Enos, Levrero Massimo, Zoulim Fabien, Wandeler Gilles, Rauch Andri, Swiss HIV Cohort Study (SHCS)

Citation

Begré L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, Béguelin C, Rockstroh J, Günthard H, Calmy A, Cavassini M, Stoeckle M, Schmid P, Bernasconi E, Levrero M, Zoulim F, Wandeler G, Rauch A, Swiss HIV Cohort Study (SHCS). Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. HIV Med 2023; 25:291-298.

Type

Journal Paper/Review (English)

Journal

HIV Med 2023; 25

Publication Date

Oct 10, 2023

Issn Electronic

1468-1293

Pages

291-298

Brief description/objective

Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study.